Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 16 of 16 for “"Sorafenib"”.

  1. Mechanisms of Reversible Sorafenib Resistance in Hepatocellular Carcinoma

    … The anti-angiogenic tyrosine kinase inhibitor sorafenib is the only approved treatment for advanced hepatocellular carcinoma (HCC) patients. Its efficacy is further hindered by intrinsic (upfront) and acquired drug resistance (initial response and subsequent relapse) and a lack of alternative …

    toronto-retro Repository record for Mechanisms of Reversible Sorafenib Resistance in Hepatocellular Carcinoma (opens in a new tab)

  2. Tyrosinkinaseinhibition bei humanen Non-Hodgkin-Lymphomen: Präklinische Evaluation von Sorafenib

    … eines mehrere Kinasen inhibierenden Moleküls, Sorafenib, bei verschiedenen aggressiven Lymphomen umfassend in vitro analysiert. Es konnte gezeigt werden, dass Sorafenib die Viabilität bereits bei geringen Konzentrationen in Abhängigkeit von Dosis und Zeit signifikant reduzierte. …

    goettingen Repository record for Tyrosinkinaseinhibition bei humanen Non-Hodgkin-Lymphomen: Präklinische Evaluation von Sorafenib (opens in a new tab)

  3. Effetti di Sorafenib, Imatinib e CORM-A1 in un modello pre-clinico di fibrosi epatica.

    … - Imatinib, dell’inibitore dell’angiogenesi - Sorafenib, somministrati da soli o in associazione, e del rilasciatore di monossido di Carbonio - CORM-A1, nel ridurre la progressione del processo fibrogenetico in un modello di danno epatico indotto in topi Balb/C da somministrazioni ripetute di …

    catania Repository record for Effetti di Sorafenib, Imatinib e CORM-A1 in un modello pre-clinico di fibrosi epatica. (opens in a new tab)

  4. Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos.

    … (erlotinib, imatinib, lapatinib, pazopanib, sorafenib y sunitinib) y las consecuentes modificaciones de dosis realizadas. Material y método: estudio analítico retrospectivo en el que se han incluido 74 pacientes en tratamiento con TKIs, a los que se les ha realizado TDM y recomendación de …

    murcia-diss Repository record for Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos. (opens in a new tab)

  5. Valutazione della terapia chirurgica con resezione e ricostruzione vascolare e della terapia oncologica nei carcinomi della tiroide localmente avanzati

    … second-look chirurgico ed eventuale terapia con Sorafenib; il secondo (braccio di controllo) comprende i pazienti che hanno ricevuto solo trattamento con Sorafenib. Tutti i pazienti reclutati erano già stati sottoposti a trattamento radiometabolico con 131I, ma refrattari al up-take di 131I. In …

    catania Repository record for Valutazione della terapia chirurgica con resezione e ricostruzione vascolare e della terapia oncologica nei carcinomi della tiroide localmente avanzati (opens in a new tab)

  6. Design of Functional Polymeric Micelles as a Carrier for Anticancer Drug Delivery

    … of anti-cancer drugs of choice, doxorubicin or sorafenib. The drug-loaded polycarbonate micellar structures were fabricated, characterized and investigated in vitro cell culture and in vivo cancer models. Functional groups for active targeting to tumor tissues were also assessed. The …

    nus Repository record for Design of Functional Polymeric Micelles as a Carrier for Anticancer Drug Delivery (opens in a new tab)

  7. Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach.

    … with a specific anti-angiogenic compound (Sorafenib) and a non-specific sompound (Combretastatin). The anti-proliferative, cytotoxic activities of the metronomic combinatorial schedules were assessed on microvascular endothelial cells and cancer cells using an MTT proliferation assay. …

    hull Repository record for Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach. (opens in a new tab)

  8. Metformin as a potential therapy for malignant astrocytoma

    … pairing with metformin. The kinase inhibitor sorafenib, showed synergism (CI ≤ 1) in eight GBM cell cultures. Flow cytometry of metformin treated GBM cells showed no significant increase (p>0.005) in apoptotic cell populations. Caspase 3/7 levels showed no significant increase post metformin …

    wlv Repository record for Metformin as a potential therapy for malignant astrocytoma (opens in a new tab)

  9. Roles For B-Raf Kinase In The Specific Regulation of Α4Β1 Integrin In T Cells

    … We show chemical inhibition of RAF by Sorafenib or shRNA-mediated knockdown of B-Raf reduces T cell resistance to shear stress to α4β1 integrin ligands vascular cell adhesion molecule-1 (VCAM-1) and fibronectin (FN), while inhibition of MEK/ERK by U0126 had no effect. Microscopy showed …

    uthsc Repository record for Roles For B-Raf Kinase In The Specific Regulation of Α4Β1 Integrin In T Cells (opens in a new tab)

  10. Κλινική θεραπεία του οστεοσαρκώματος, παρόν και μέλλον

    … επιτυχία οι αναστολείς της κινάσης της τυροσίνης Sorafenib, Regorafenib με μικρή αλλά ελπιδοφόρα παράταση του προσδόκιμου επιβίωσης σε μεταστατικούς ασθενείς 6 και 4 μηνών αντίστοιχα. Στο επίπεδο της χειρουργικής αντιμετώπισης του οστεοσαρκώματος η χρήση αρθρωτών προθέσεων δίνει την δυνατότητα …

    athens Repository record for Κλινική θεραπεία του οστεοσαρκώματος, παρόν και μέλλον (opens in a new tab)

  11. The Role of Cellular Prion Protein in the Development of Schwannomas and other Merlin-Deficient Tumours

    … patients, either alone or in combination with Sorafenib and p-gp inhibitor Valspodar (PSC833). An inhibitor of LR/37/67kDa/PrP interaction, NSC47924, or Bortezomib, a proteasome/NFκB inhibitor which has been approved for the treatment of multiple myeloma, could also be of beneficial therapeutic …

    plymouth Repository record for The Role of Cellular Prion Protein in the Development of Schwannomas and other Merlin-Deficient Tumours (opens in a new tab)

  12. Lmw-E Mediates Mammary Tumorigenesis By Deregulating Acinar Morphogenesis & Generating Cancer Stem Cells

    … plus either rapamycin (mTOR inhibitor) or sorafenib (b-raf inhibitor)</p> <p>effectively prevented aberrant acinar formation in LMW-E-expressing cells by</p> <p>inducing the G1/S cell cycle arrest. In addition, the LMW-E-expressing tumor cells</p> <p>exhibit phenotypes characteristic of the …

    uthsc Repository record for Lmw-E Mediates Mammary Tumorigenesis By Deregulating Acinar Morphogenesis & Generating Cancer Stem Cells (opens in a new tab)

  13. Molecular Characterization of Glioblastoma Cancer Stem Cells

    … sensitive to the kinase inhibitors, WP1066 and Sorafenib, and targeted inhibition of STAT3 and ANGPTL4 was found to decrease stem cell marker expression within tumors and lead to tumor regression. Taken together, these studies reveal that multiple CSC populations exist within GBM that drive …

    tenn-hsc Repository record for Molecular Characterization of Glioblastoma Cancer Stem Cells (opens in a new tab)

  14. Analysis of Out-of-Pocket Expenditures of Oral Oncologics for Tennessee Recipients of Medicare Part D

    … the drugs in the study, imatinib, lenalidomide, sorafenib, erlotinib, dasatinib, sunitinib, vorinostat, nilotinib, and lapatinib, the annual out-of-pocket costs for each drug varied from $0 to a maximum of $1,133, based on plan design. Bivariate regression analysis showed that monthly premiums, …

    tenn-hsc Repository record for Analysis of Out-of-Pocket Expenditures of Oral Oncologics for Tennessee Recipients of Medicare Part D (opens in a new tab)

  15. TDiscovery and Development of Novel Therapeutic Agents for Advanced Melanoma

    … of these new compounds have activity similar to Sorafenib, an FDA-approved drug that has been tested clinically in melanoma patients.</p> <p>To further expand our understanding of SARs and to potentially identify new platforms for active compounds, Dr. Li and Dr. Seibel explored a compound …

    tenn-hsc Repository record for TDiscovery and Development of Novel Therapeutic Agents for Advanced Melanoma (opens in a new tab)

  16. NANOPARTICELLE A BASE DI CICLODESTRINE PER APPLICAZIONI BIOMEDICALI

    Negli ultimi anni lo studio di nuovi macro e nano sistemi ha rappresentato uno degli argomenti di maggior interesse in campo scientifico. L’obiettivo è quello di aumentare l’efficacia della terapia tradizionale soprattutto per la cura di pazienti con malattie croniche, sottoposti a trattamenti per …

    catania Repository record for NANOPARTICELLE A BASE DI CICLODESTRINE PER APPLICAZIONI BIOMEDICALI (opens in a new tab)